| ○種別 (必須): | □ | 学術論文 (審査論文)
| [継承] |
| ○言語 (必須): | □ | 英語
| [継承] |
| ○招待 (推奨): |
| ○審査 (推奨): |
| ○カテゴリ (推奨): |
| ○共著種別 (推奨): | □ | 国内共著 (徳島大学内研究者と国内(学外)研究者との共同研究 (国外研究者を含まない))
| [継承] |
| ○学究種別 (推奨): |
| ○組織 (推奨): |
| ○著者 (必須): | 1. | (英) Mure Kanae (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 2. | (英) Ishikawa Hideki (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 3. | (英) Mutoh Michihiro (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 4. | (英) Horinaka Mano (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 5. | (英) Otani Takahiro (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 6. | (英) Suzuki Sadao (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 7. | (英) Wakabayashi Keiji (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 8. | (英) Sakai Toshiyuki (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 9. | 佐藤 康史 ([徳島大学.大学院医歯薬学研究部.医学域.連携研究部門(医学域).寄附講座系(医学域).地域消化器・総合内科学])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 10. | (英) Doyama Hisashi (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 11. | (英) Tajika Masahiro (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 12. | (英) Tanaka Shinji (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 13. | (英) Horimatsu Takahiro (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 14. | (英) Takeuchi Yoji (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 15. | (英) Kashida Hiroshi (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 16. | (英) Tashiro Jun (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 17. | (英) Ezoe Yasumasa (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 18. | (英) Nakajima Takeshi (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 19. | (英) Ikematsu Hiroaki (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 20. | (英) Hori Shinichiro (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 21. | 高山 哲治
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 22. | (英) Ohda Yoshio (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| ○題名 (必須): | □ | (英) 101.Efficacy of Low-Dose Aspirin in Colorectal Cancer Risk Prevention is Dependent on ADH1B and ALDH2 Genotype in Japanese Familial Adenomatous Polyposis Patients. (日)
| [継承] |
| ○副題 (任意): |
| ○要約 (任意): | □ | (英) Aspirin has gained great attention as a cancer preventive agent. Our previous study revealed that the low-dose aspirin prevents colorectal tumor recurrence in Japanese patients with colorectal adenomas and/or adenocarcinomas, whereas aspirin increases risks in smokers and has no effects on regular drinkers. Our recent study revealed that aspirin reduces polyp growth in Japanese patients with familial adenomatous polyposis (FAP). In this study, we have studied the association of genotypes of alcohol metabolizing enzymes (ADH1B and ALDH2) on aspirin's efficacy of suppressing polyp growth (5 mm) in a total of 81 Japanese patients with FAP. Our study revealed that aspirin showed significant preventive effects for patients with ADH1B-AA and AA+GA types [OR = 0.21; 95% confidence interval (CI), 0.05-0.95, and OR = 0.31; 95% CI, 0.10-0.95, respectively], and for patients with ALDH2-GG and GG+GA types (OR = 0.10; 95% CI, 0.01-0.92, and OR = 0.29; 95% CI, 0.09-0.94, respectively), but not for patients with ADH1B-GG and GA+GG types, and ALDH2-AA and GA+AA types. In addition, substantial preventive effects of aspirin were seen for patients with ADH1B-AA type who do not drink regularly (<3 times/week, OR = 0.11; 95% CI, 0.02-0.78), where a statistically significant interaction between aspirin and ADH1B was observed (P interaction = 0.036). Results from this exploratory study strongly indicate that aspirin is beneficial in prevention of polyp growth for patients with FAP with ADH1B-AA and AA+GA types, and ALDH2-GG and GG+GA types. Taken together, we propose ADH1B and ALDH2 as candidate markers for the personalized prevention by aspirin. Aspirin is beneficial to patients with FAP with ADH1B-AA and AA+GA types or ALDH2-GG and GG+GA types. ADH1B and ALDH2 genotypes can be the markers for the personalized prevention of colorectal cancer by aspirin. (日)
| [継承] |
| ○キーワード (推奨): | 1. | (英) Humans (日) (読)
| [継承] |
| 2. | (英) Adenomatous Polyposis Coli (日) (読)
| [継承] |
| 3. | (英) Aldehyde Dehydrogenase, Mitochondrial (日) (読)
| [継承] |
| 4. | (英) Aspirin (日) (読)
| [継承] |
| 5. | (英) Colorectal Neoplasms (日) (読)
| [継承] |
| 6. | (英) East Asian People (日) (読)
| [継承] |
| 7. | (英) Genotype (日) (読)
| [継承] |
| 8. | (英) Neoplasm Recurrence, Local (日) (読)
| [継承] |
| 9. | (英) Polymorphism, Genetic (日) (読)
| [継承] |
| ○発行所 (推奨): |
| ○誌名 (必須): | □ | Cancer Research Communications ([American Association for Cancer Research])
(eISSN: 2767-9764)
| ○ISSN (任意): | □ | 2767-9764
ISSN: 2767-9764
(eISSN: 2767-9764) Title: Cancer research communicationsTitle(ISO): Cancer Res CommunPublisher: American Association for Cancer Research Inc. (NLM Catalog)
(Scopus)
(CrossRef)
(Scopus information is found. [need login]) | [継承] |
| [継承] |
| ○巻 (必須): | □ | 2
| [継承] |
| ○号 (必須): | □ | 6
| [継承] |
| ○頁 (必須): | □ | 483 488
| [継承] |
| ○都市 (任意): |
| ○年月日 (必須): | □ | 西暦 2022年 6月 23日 (令和 4年 6月 23日)
| [継承] |
| ○URL (任意): |
| ○DOI (任意): | □ | 10.1158/2767-9764.CRC-22-0088 (→Scopusで検索)
| [継承] |
| ○PMID (任意): | □ | 36923554 (→Scopusで検索)
| [継承] |
| ○CRID (任意): |
| ○Scopus (任意): | 1. | 2-s2.0-85195205659
| [継承] |
| ○researchmap (任意): |
| ○評価値 (任意): |
| ○被引用数 (任意): |
| ○指導教員 (推奨): |
| ○備考 (任意): | 1. | (英) Derived from Scopus.AUID(55555883900) (日)
| [継承] |
| 2. | (英) Modified using PubMed.PMID(36923554) (日)
| [継承] |